Comparison of pathologic response & safety in standard neoadjuvant therapy versus concomitant boost radiotherapy in patient with localy advanced rectal cancer.

Comparison of pathologic response & safety in standard neoadjuvant therapy versus concomitant boost radiotherapy in patient with localy advanced rectal cancer reffered to cancer institute from 2021 to 2024.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211108052999N1

Enrollment

100

Registered

2021-11-25

Start date

2021-11-22

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer. Malignant neoplasm of rectum

Interventions

Intervention 1: Intervention group: In intervention group, the chemotherapy regimen is similar to the first group, and in radiotherapy, in addition to 4500 cGy per pelvis, the patient receives 1100 c

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Good performance (kps> 70) T3,T4 N0 in 12 of anal verge Node+ T2N0 in 5 cm of anal verge No metastasis

Exclusion criteria

Exclusion criteria: Incomplete chemotherapy or radiotherapy Recurrence Chemotherapy before radiotherapy Metastasis

Design outcomes

Primary

Measure	Time frame
Pathologic response. Timepoint: After surgery. Method of measurement: Tissue pathological assesment.;Treatment adverse effect. Timepoint: Weekly during treatment. Method of measurement: Examination, CBC and renal function test.	—

Secondary

Measure	Time frame
Clinical response. Timepoint: Before intervention and before surgery. Method of measurement: MRI.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Aghili

Tehran University of Medical Sciences

aghili@sina.tums.ac.ir+98 21 6119 2585

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026